

## **Biofrontera to Present at the 19th Annual Rodman & Renshaw Global Investment Conference**

**Leverkusen, Germany, August 30, 2017** – Biofrontera AG (ISIN: DE0006046113), a dermatology company specializing in the treatment of sun-induced skin cancer, today announced that it will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference, being held on September 10-12, 2017 at The Lotte New York Palace Hotel in New York City.

Thomas Schaffer, Biofrontera's Chief Financial Officer, will provide an overview of the Company's business during the presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

If you are an institutional investor, and would like to attend the Company's presentation, please click on the link ([www.rodmanevents.com](http://www.rodmanevents.com)) to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

Details for the presentation are as follows:

Date: Tuesday, September 11, 2017  
Time: 10:50 a.m. EDT  
Room: Adams

**-End-**

**Enquiries, please contact:**

+49 (0) 214 87 63 2 0

press@biofrontera.com

**Biofrontera AG**

Thomas Schaffer, Chief Financial Officer

**Biofrontera AG**

Hemmelrather Weg 201 | D-51377 Leverkusen, Germany  
Phone: +49 214 87632-0 | Telefax: +49 214 87632-90  
info@biofrontera.com | www.biofrontera.com

Supervisory board: Dr. Ulrich Granzer (Chairman) | Jürgen Baumann (Vice-Chairman)  
Executive board: Prof. Dr. rer. nat. Hermann Lübbert (CEO)  
Christoph Dünwald (CCO) | Thomas Schaffer (CFO)  
**Commercial register:** Handelsregister Köln | **Register number:** HR B 49717 (AG)  
**VAT-identification number according to § 27 a UStG VAT act:** DE 812374102

## news release

**IR Germany: Brainwell Asset Solutions** +49 (0) 152 08931514

Jürgen Benker

**IR UK: Seton Services** +44(0) 20 7729 0805

Toni Vallen

**IR and PR US: The Ruth Group**

IR: Tram Bui +1 646-536-7035

PR: Kirsten Thomas +1 508-280-6592

### About Biofrontera:

Biofrontera AG is a biopharmaceutical company specializing in the development, sale and distribution of dermatological drugs and medical cosmetics. The Leverkusen, Germany-based company which has approximately 100 employees worldwide, develops and distributes innovative products for the care, protection and treatment of the skin. Biofrontera's combination lead product is topical prescription drug Ameluz® and medical device BF-RhodoLED® for the photodynamic therapy (PDT) treatment of superficial skin cancer and its precursors. Ameluz® has been marketed in the EU since 2012 and in the U.S. since 2016. The Company also markets the Belixos® dermocosmetics series in the EU, which offers specialized care for damaged or diseased skin.

Biofrontera is the first German, founder-led pharmaceutical company to obtain both EU and U.S. approval for a medical drug it has developed itself. The Biofrontera Group was established in 1997 by current CEO, Prof. Dr. Hermann Lübbert, and is listed on the Frankfurt Stock Exchange (Prime Standard).

### [www.biofrontera.com](http://www.biofrontera.com)

*This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.*

### Biofrontera AG

Hemmelrather Weg 201 | D-51377 Leverkusen, Germany  
Phone: +49 214 87632-0 | Telefax: +49 214 87632-90  
info@biofrontera.com | www.biofrontera.com

Supervisory board: Dr. Ulrich Granzer (Chairman) | Jürgen Baumann (Vice-Chairman)  
Executive board: Prof. Dr. rer. nat. Hermann Lübbert (CEO)  
Christoph Dünwald (CCO) | Thomas Schäffer (CFO)  
**Commercial register:** Handelsregister Köln | **Register number:** HR B 49717 (AG)  
**VAT-identification number according to § 27 a UStG VAT act:** DE 812374102